Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • CTR Exam Preparation and Review Webinar Series March 2019

    Contains 5 Component(s)

    The NAACCR CTR Exam Preparation & Review Webinar Series offers online interactive instruction with live instructors. The course includes eight 2-hour sessions carefully prepared to reflect the changes to the 2019 CTR exam.

    Welcome to the NAACCR CTR Exam Preparation and Review Webinar Series page!

    If you would like to be a part of the discussions within the group, go to the Discussion tab and click on the box Yes, I want to receive emails when anyone else posts a comment here. 

    image

    We recommend if you have any questions in regards to the webinar series content please post them in the Discussions tab so that everyone will be able to view.  

    For more information about the CTR Exam visit NCRA's Council on Certification.

  • Producing Cancer Statistics at the Census Tract Level: A Louisiana Story

    Contains 1 Component(s) Recorded On: 11/14/2018

    During the 2017 Louisiana Legislative Session, a new law was signed requiring that the Louisiana Tumor Registry (LTR) produce and release cancer incidence counts and rates at the census tract level. Previously, cancer statistics could be released to the public at the parish (county) level. To comply with this law, the LTR convened a team, including experts from NCI-SEER and IMS, to develop the appropriate methodology to produce incidence rates at the census tract level while ensuring rate stability and patient confidentiality. The objective of this presentation is to describe the LTR's experience with identifying the appropriate population source, selecting the time period for the analysis, and producing reliable cancer statistics at the census tract level, as well as to share a summary of the results.

    During the 2017 Louisiana Legislative Session, a new law was signed requiring that the Louisiana Tumor Registry (LTR) produce and release cancer incidence counts and rates at the census tract level. Previously, cancer statistics could be released to the public at the parish (county) level. To comply with this law, the LTR convened a team, including experts from NCI-SEER and IMS, to develop the appropriate methodology to produce incidence rates at the census tract level while ensuring rate stability and patient confidentiality. The objective of this presentation is to describe the LTR's experience with identifying the appropriate population source, selecting the time period for the analysis, and producing reliable cancer statistics at the census tract level, as well as to share a summary of the results.

  • Setting up NCD Surveillance in an island context: Lessons from the Pacific

    Contains 1 Component(s)

    Setting up NCD Surveillance in an island context: Lessons from the Pacific

    Setting up NCD Surveillance in an island context: Lessons from the Pacific

    Please click "Handouts" tab above to access material.

  • International Registry Review Questionnaire

    Contains 1 Component(s)

    International Registry Review Questionnaire

    International Registry Review Questionnaire

  • Regional Workshop On Using Cancer Registry Data to Inform Cancer Prevention and Control Policy/Research

    Contains 1 Component(s)

    Regional Workshop On Using Cancer Registry Data to Inform Cancer Prevention and Control Policy/Research

    This session will focus on Regional Workshop On Using Cancer Registry Data to Inform Cancer Prevention and Control Policy/Research.

    Brenda Edwards

    Senior Advisor for Cancer Surveillance

    Brenda K. Edwards, PhD, has been with the Surveillance Research Program (SRP) and its predecessor organizations at the National Cancer Institute (NCI) since 1989, serving as SRP's Associate Director from 1990-2011. She has been involved in cancer prevention and control since its formative days early in the 1980s. Dr. Edwards' research has focused on the full spectrum of cancer surveillance research, including risk factors, patterns of care, behavioral studies and survivorship, statistical methodology, and analytic studies.

    Under her leadership, NCI's Surveillance, Epidemiology, and End Results (SEER) Program has become an important resource for monitoring the nation's cancer burden and for measuring progress in cancer control. Dr. Edwards has played a major role in preparing and disseminating the “Annual Report to the Nation on the Status of Cancer."

    Dr. Edwards has received numerous awards, including the North American Association of Central Cancer Registries Calum S. Muir Memorial Award, in recognition for her work in cancer surveillance and registration. She has co-authored more than 100 peer-reviewed publications.

  • Survey Course: Understanding Population-Based Cancer Registries Course

    Contains 15 Component(s)

    Survey Course: Understanding Population-Based Cancer Registries Course

    Introduction to Cancer Registries and Cancer Surveillance

    1. Public Health Surveillance Introduction & Fundamentals
    2. Establishing an Effective Population-based Cancer Registry System

    Registry Operations

    1. Casefinding
    2. Follow-up
    3. Data Editing
    4. Record consolidation
    5. Death clearance

    Registry Management

    1. Registry Development
    2. Data Quality and Completeness
    3. Ethics & confidentiality
    4. Data Management – IT resources

    Uses of Population-Based Registry Data

    1. Calculation and Assessment of Survival Rates
    2. Calculation and Assessment of Cancer Incidence
    3. Using Central Cancer Registry Data for Cancer Control and Cancer Research
  • RDU Webinar Series: Online Interactive Tool to Improve the Understanding of Survival Statistics

    Contains 1 Component(s) Recorded On: 09/14/2017

    Background There are a variety of ways to quantify cancer survival with each measure having advantages and disadvantages. For example, relative/net survival is useful for making fair comparisons between population groups and over time, but is of less relevance to clinicians or patients. The differences between the various measures and how they should be interpreted has led to confusion among scientists, the media, health care professionals and patients. Purpose and methods. We have developed an online interactive tool to help improve the understanding of a variety of cancer survival measures and how these vary between patients. Its primary purpose is to function as an aid in the interpretation of a variety of commonly reported, important and more complex cancer survival measures that are available from fitting statistical models. The interpretation is facilitated through the use of dynamic interactive graphics available using an online interactive tool. The interactivity improves understanding of these measures and how survival or mortality may vary by age and sex. Routine measures of cancer survival are reported, such as net and all-cause survival. In addition, individualised estimates using crude probabilities are often more appropriate for patients or health care professionals. The results are presented in a variety of ways, including graphs, “people charts”, tables and descriptive text using natural frequencies. All results are updated immediately when using drag bars, drop-down menus or radio buttons. This immediate feedback together with the simple text descriptions leads to both better understanding of individual risk and the differences between the various measures. Results and conclusion The online tool is in final testing using English data for a range of cancer sites. The tool is available at www.interpret.le.ac.uk. We have plans to further develop the interactive tool by incorporating data from different countries and from statistical models that incorporate more disease characteristics (e.g. stage, grade and tumour size).

    Background

    There are a variety of ways to quantify cancer survival with each measure having advantages and disadvantages. For example, relative/net survival is useful for making fair comparisons between population groups and over time, but is of less relevance to clinicians or patients. The differences between the various measures and how they should be interpreted has led to confusion among scientists, the media, health care professionals and patients.

    Purpose and methods.

    We have developed an online interactive tool to help improve the understanding of a variety of cancer survival measures and how these vary between patients. Its primary purpose is to function as an aid in the interpretation of a variety of commonly reported, important and more complex cancer survival measures that are available from fitting statistical models. The interpretation is facilitated through the use of dynamic interactive graphics available using an online interactive tool. The interactivity improves understanding of these measures and how survival or mortality may vary by age and sex. Routine measures of cancer survival are reported, such as net and all-cause survival. In addition, individualised estimates using crude probabilities are often more appropriate for patients or health care professionals. The results are presented in a variety of ways, including graphs, “people charts”, tables and descriptive text using natural frequencies. All results are updated immediately when using drag bars, drop-down menus or radio buttons. This immediate feedback together with the simple text descriptions leads to both better understanding of individual risk and the differences between the various measures.

    Results and conclusion

    The online tool is in final testing using English data for a range of cancer sites. The tool is available at www.interpret.le.ac.uk.  We have plans to further develop the interactive tool by incorporating data from different countries and from statistical models that incorporate more disease characteristics (e.g. stage, grade and tumour size).  

    Paul C Lambert

    Paul C Lambert is a professor of Biostatistics working in the Biostatistics Research Group in the Department of Health Sciences at the University of Leicester, UK. He also part-time in the Biostatistics Group in the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

  • RDU Webinar Series: Identifying Target Areas for Colorectal Cancer Screening in Louisiana through Geospatial Analysis

    Contains 1 Component(s) Recorded On: 08/10/2017

    The Louisiana Tumor Registry (LTR), along with the Louisiana Colorectal Cancer Roundtable and geospatial experts from NCI, Westat, and Temple University, collaborated to map colorectal cancer in Louisiana to support the National Colorectal Cancer Roundtable’s “80% by 2018” initiative. The overall goal of the project was to use multiple data sources and geospatial analyses in order to identify the places and high-risk populations who may benefit the most from screening interventions. Through this webinar, the LTR will share its experiences with address cleaning and geospatial analyses, as well as present the resulting maps and implications for screening in Louisiana.

    The Louisiana Tumor Registry (LTR), along with the Louisiana Colorectal Cancer Roundtable and geospatial experts from NCI, Westat, and Temple University, collaborated to map colorectal cancer in Louisiana to support the National Colorectal Cancer Roundtable’s “80% by 2018” initiative.  The overall goal of the project was to use multiple data sources and geospatial analyses in order to identify the places and high-risk populations who may benefit the most from screening interventions.  Through this webinar, the LTR will share its experiences with address cleaning and geospatial analyses, as well as present the resulting maps and implications for screening in Louisiana.

    Lauren S. Maniscalco, MPH

    Lauren Maniscalco has a Bachelor of Science degree in Biology from the University of Louisiana at Lafayette and a Master of Public Health degree in Epidemiology from the Louisiana State University Health Sciences Center School of Public Health.  She has been working for the Louisiana Tumor Registry since 2010 and is currently the Registry Liaison.

    Kevin Henry, PhD, MA

    Kevin Henry earned his PhD in Geography from McGill University and is currently an associate professor in the Department of Geography and Urban Studies at Temple University and a member of Fox Chase Cancer Center’s Cancer Prevention and Control Program.  He is a medical geographer focusing on the intersection between geography, public health, and epidemiology.

    Yong Yi, PhD, MS

    Yong Yi earned her PhD in Electrical Engineering from the University of Wyoming and a Master of Science degree in Statistics from Texas A&M University.  She has been working for the Louisiana Tumor Registry since 2016 and is currently the data manager.

  • RDU Webinar Series: Precision Cancer Medicine: Focus on Children

    Contains 1 Component(s) Recorded On: 02/15/2017

    This webinar is part of a series sponsored by the Research & Data Use Steering Committee. The idea is to bring high quality presentations that were presented during the annual conference to a wider audience via webinar. If you have seen a presentation at the annual conference, or elsewhere, that you feel would benefit the larger NAACCR community, please suggest it be presented in this forum.

    Oncologists heave been personalizing patient care for many years. When oncologists review slides with a pathologist to arrive at an accurate diagnosis or review radiology scans to determine stage in order to determine the most appropriate treatment regimen, they are personalizing patient care. The significant advances that have occurred in gene sequencing technologies and the development of new more targeted drugs has allowed oncologists to personalize care even more by matching gene alterations (mutations, copy number alterations and translocations) found in an individuals own tumor to targeted therapies. The term precision cancer medicine is now used most often used to refer to this type of care. Dr. Katherine Janeway is pediatric hematologist-oncologist and researcher with joint appointments at Harvard Medical School, Dana-Farber Cancer Institute, and Children’s Hospital, Boston.  She is the Director of the Pediatric Solid Tumor Program, a member of the Dana-Farber/Harvard Cancer Center Genetics Program and leader of the Pediatric Oncology Precision Cancer Medicine Initiative. This presentation will provide an overview of the advances in genomics and targeted therapy that make precision cancer medicine possible and will review the research being conducted in Precision Cancer Medicine with a focus on clinical sequencing studies, basket trials and pediatric oncology.

    Katherine Janeway, MD, MMSc

    Dr. Katherine Janeway is  a pediatric hematologist-oncologist and researcher with joint appointments at Harvard Medical School, Dana-Farber Cancer Institute, and Children’s Hospital, Boston.  She is the Director of the Pediatric Solid Tumor Program, a member of the Dana-Farber/Harvard Cancer Center Genetics Program and leader of the Pediatric Oncology Precision Cancer Medicine Initiative.